Plerixafor Salvage Is Safe and Effective in Hard-to-Mobilize Patients Undergoing Chemotherapy and Filgrastim-Based Peripheral Blood Progenitor Cell Mobilization
dc.contributor.author | Awan, Farrukh T. | |
dc.contributor.author | Kochuparambil, S. Thomas | |
dc.contributor.author | DeRemer, David | |
dc.contributor.author | Cumpston, Aaron | |
dc.contributor.author | Craig, Michael | |
dc.contributor.author | Jillella, Anand | |
dc.contributor.author | Hamadani, Mehdi | |
dc.date.accessioned | 2012-10-26T20:30:44Z | |
dc.date.available | 2012-10-26T20:30:44Z | |
dc.date.issued | 2012-04-10 | en_US |
dc.identifier.citation | J Oncol. 2012 Apr 10; 2012:931071 | en_US |
dc.identifier.issn | 1687-8469 | en_US |
dc.identifier.pmid | 22570654 | en_US |
dc.identifier.doi | 10.1155/2012/931071 | en_US |
dc.identifier.uri | http://hdl.handle.net/10675.2/787 | |
dc.description.abstract | The combination of filgrastim (G-CSF) and plerixafor is currently approved for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin lymphoma and multiple myeloma undergoing autologous peripheral blood hematopoietic cell transplantation. However, chemotherapy and G-CSF-based mobilization remains a widely used strategy for peripheral blood progenitor cell collection. In this paper we describe our experience from two North American transplant centers in a series of patients who received salvage plerixafor while failing chemotherapy and G-CSF mobilization. Patients received a median of two doses of plerixafor salvage upon failure to mobilize adequate number of peripheral blood progenitor cells at neutrophil recovery. The use of plerixafor was associated with a 2.4-fold increase in peripheral blood CD34+ cell count and 3.9-fold increase in total CD34+ cell yield. All patients were able to collect â ¥2 Ã 106 CD34+â cells/kg with this approach. These results were more pronounced in patients with a higher CD34+ cell count at the time of the first plerixafor dose. Interestingly, peripheral blood white blood cell count was not shown to correlate with a response to plerixafor. Our results provide safety and efficacy data for the use of plerixafor in patients who are destined to fail chemomobilization. | |
dc.rights | Copyright © 2012 Farrukh T. Awan et al. | en_US |
dc.subject | Research Article | en_US |
dc.title | Plerixafor Salvage Is Safe and Effective in Hard-to-Mobilize Patients Undergoing Chemotherapy and Filgrastim-Based Peripheral Blood Progenitor Cell Mobilization | en_US |
dc.type | Article | en_US |
dc.identifier.pmcid | PMC3335320 | en_US |
dc.contributor.corporatename | Department of Medicine | |
dc.contributor.corporatename | Department of Pharmacology and Toxicology | |
refterms.dateFOA | 2019-04-10T00:50:51Z | |
html.description.abstract | The combination of filgrastim (G-CSF) and plerixafor is currently approved for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin lymphoma and multiple myeloma undergoing autologous peripheral blood hematopoietic cell transplantation. However, chemotherapy and G-CSF-based mobilization remains a widely used strategy for peripheral blood progenitor cell collection. In this paper we describe our experience from two North American transplant centers in a series of patients who received salvage plerixafor while failing chemotherapy and G-CSF mobilization. Patients received a median of two doses of plerixafor salvage upon failure to mobilize adequate number of peripheral blood progenitor cells at neutrophil recovery. The use of plerixafor was associated with a 2.4-fold increase in peripheral blood CD34+ cell count and 3.9-fold increase in total CD34+ cell yield. All patients were able to collect â ¥2 Ã 106 CD34+â cells/kg with this approach. These results were more pronounced in patients with a higher CD34+ cell count at the time of the first plerixafor dose. Interestingly, peripheral blood white blood cell count was not shown to correlate with a response to plerixafor. Our results provide safety and efficacy data for the use of plerixafor in patients who are destined to fail chemomobilization. |